| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/10/2001 | WO2001032038A1 Fibrous-liponutritional complexes and compositions containing them |
| 05/10/2001 | WO2001032036A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | WO2001032031A2 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | WO2001032029A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 05/10/2001 | WO2001019378A3 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 05/10/2001 | WO2001008505A3 Methods for suppressing appetite and enhancing exercise and recovery |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2001000183A3 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 05/10/2001 | WO2000072885A3 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 05/10/2001 | WO2000047720A3 Pancreatic progenitor cells, methods and uses related thereto |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389931A1 Antidiabetic formulation and method |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389704A1 Compositions comprising edible oils and phytosterols and/or phytostanols substantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease, and its underlying conditions |
| 05/10/2001 | CA2389703A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389616A1 Liver selective therapy |
| 05/10/2001 | CA2389605A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | CA2389574A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2389208A1 Process for the preparation of oxyiminoalkanoic acid derivatives |
| 05/10/2001 | CA2388955A1 Recombinant fusion molecules |
| 05/10/2001 | CA2388339A1 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387799A1 19 human secreted proteins |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387620A1 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387135A1 Polymorphic forms of sertraline hydrochloride |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385665A1 Modulation of enos activity and therapeutic uses thereof |
| 05/10/2001 | CA2358921A1 Oxetanone derivatives |
| 05/10/2001 | CA2325201A1 Methods of administering apo b-secretion/mtp inhibitors |
| 05/10/2001 | CA2324801A1 Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| 05/10/2001 | CA2324800A1 Use of apo b secretion/mtp inhibitors |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097920A1 Intermediate for condensed benzazepine derivatives |
| 05/09/2001 | EP1097716A1 Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (TRH) |
| 05/09/2001 | EP1097713A1 Inhibitors of the inositol polyphosphate 5-phosphatase ship-2 molecule |
| 05/09/2001 | EP1097710A2 Combination product for treating niddm |
| 05/09/2001 | EP1097709A2 Use of corticotropin releasing factor antagonists for treating syndrome X |
| 05/09/2001 | EP1097202A2 Human transport protein homologs |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097149A1 Bicyclohexane derivatives |
| 05/09/2001 | EP1097145A1 Polyhydroalkylpyrazine derivatives and their preparation and medicines containing them |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1097129A1 N-benzocycloalkyl-amide derivatives and their use as medicaments |
| 05/09/2001 | EP1096940A1 Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | EP1033131A4 Composition of ingredients for a beverage having a delayed aversion effect |
| 05/09/2001 | CN1294597A Methods for treatment of diabetes using peptide analogues of insulin |
| 05/09/2001 | CN1294515A Compsn. for reducing serum cholesterol levels |
| 05/09/2001 | CN1294513A Pharmaceutically active morpholinol |
| 05/09/2001 | CN1294120A Process for preparing optical-purity fluoxetine |
| 05/09/2001 | CN1293983A Hypolipemic medicine and its preparing process and application |
| 05/09/2001 | CN1293981A Hypolipemic 'Tongluowan' |
| 05/09/2001 | CN1293972A Tea for nourishing kidney and losing weight |
| 05/09/2001 | CN1293961A Calcium-supplementing powder 'Gaosugai' |
| 05/09/2001 | CN1293923A Cold ox horn blood tea and its preparing process |
| 05/09/2001 | CN1293918A Sea polymer as food addtive for diabetics |
| 05/09/2001 | CN1065535C Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |
| 05/08/2001 | US6229013 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 05/08/2001 | US6228861 Benign prostatic hyperplasia; anticholesterol agents; impotency; intraocular pressure; antiarrhythmia agents |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228642 Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| 05/08/2001 | CA2170289C A method of treating liver disease and like indications with vasodilating agents |
| 05/08/2001 | CA2167040C New alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
| 05/08/2001 | CA2065412C Methods of preventing and reducing the size of striae distensae lesions |
| 05/03/2001 | WO2001031051A2 Antisense modulation of protein kinase c-theta expression |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001031008A2 Human and rat fgf-20 genes and gene expression products |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001030978A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | WO2001030848A2 Nucleic acids of the human abc1 gene and applications thereof |
| 05/03/2001 | WO2001030801A1 Antisense modulation of integrin-linked kinase expression |
| 05/03/2001 | WO2001030796A1 A process for preparing acarbose with high purity |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030772A1 Compounds and their use as cysteine protease inhibitors |
| 05/03/2001 | WO2001030761A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030754A2 Micro-cluster liquids and methods of making and using them |
| 05/03/2001 | WO2001030736A2 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030392A2 Delivery of proteins across polar epithelial cell layers |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030378A1 A method of prophylaxis and treatment |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |